HUGE - Inebriation Remedy And Breakthrough MS Treatment: Meet FSD Pharma | Benzinga
Among a biotech space bursting with innovation, one company stands out as it is developing two assets at once: a ready-for-market drink that can take someone from a drinking state to mental and physical composure in record time and a potential breakthrough therapy for Multiple Sclerosis. Meet FSD Pharma (NASDAQ: HUGE), which began trading on CSE as a licensed cannabis producer. Its 650,000 sq. ft. plant brought about corresponding production gains.
"When we started out we caught the cannabis wave,” founder and CEO Zeeshan Saeed told Benzinga. FSD then moved on to trading on NASDAQ. With an interim chapter of overvaluation, a proxy war (won by management in 2021,) short-selling and general shortages in the cannabis space, the team eventually surrendered FSD’s production license and sold its facility in 2020. It then moved into the biotech world through the acquisition of Lucid Psycheceutical.
The team at Lucid is composed of world-class scientists, researchers and doctors from the University of Toronto and Stanford. It also has a connection to the Canadian government via Ontario’s ex-health minister and current FSD board member.
Alcohol Relief
"Mental alertness and detoxification” following alcohol consumption is UNBUZZD’s promise. Its developers expect, based on research, that it provides relief from inebriation, helping the body accelerate alcohol metabolism and ...